Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02429583
Other study ID # CRI-0844
Secondary ID U19AI111825
Status Terminated
Phase Phase 4
First received
Last updated
Start date May 8, 2015
Est. completion date November 2018

Study information

Verified date February 2020
Source Rockefeller University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate the effects of chronic HCV infection and corresponding innate immune activation on the immune response to HBV vaccination. We will recruit chronic HCV patients and healthy control patients for HBV vaccination. We will use RNA Sequencing (RNA-Seq), a relatively new technology for simultaneously measuring the expression of all genes, to determine patients' innate immune status, and learn how this innate immune signature is related to HBV vaccine response. We will then explore the mechanisms by which chronic HCV infection affects different immune cells and functions that are known to be important for an effective HBV vaccine response. These studies will enhance our understanding of the immune effects of chronic viral infection, establish factors that determine effective vaccine responses, and help guide vaccination strategies for HCV patients and other individuals with chronic inflammatory disease.


Description:

Vaccines have been responsible for preventing millions of deaths and extending the average human lifespan. Effective vaccines stimulate the cells of the immune system to activate genes and associated functions that bring about protective immunity. If we can better understand the factors that influence vaccine success versus failure, we may be able to improve current vaccines and/or develop new vaccines against prevalent infectious diseases.

Certain groups of people do not respond well to particular vaccines. For example, vaccines can be less effective in immunocompromised patients, elderly individuals, and people with chronic inflammatory diseases. Often it is these groups of people that have the greatest need for protection against infectious disease.

People chronically infected with hepatitis C virus (HCV) are at increased risk of serious liver disease. As a result, they should receive the hepatitis B virus (HBV) vaccine, which can protect them from infection by HBV, another virus that targets the liver. However, people chronically infected with HCV do not respond to the HBV vaccine as effectively as healthy people without HCV. Chronic HCV infection is not thought to cause general problems with the immune system, and the reasons for this poor vaccine response are poorly understood. Previous work has shown that chronic HCV infection leads to production of chemical ("innate immune") signals that can affect function of the immune system, but it is currently unknown how this might impact vaccination.


Recruitment information / eligibility

Status Terminated
Enrollment 24
Est. completion date November 2018
Est. primary completion date November 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 62 Years
Eligibility Inclusion Criteria:

- Willing to receive three doses of an FDA-approved Hepatitis B vaccine

- Volunteer chronically infected with HCV (as demonstrated by serology and/or viral load laboratory studies)

- Healthy volunteer without significant medical problems

Exclusion Criteria:

- Received any vaccine within a month prior to study vaccine

- Positive serum antibody against Hep B surface antigen and/or core Hep B core antigen

- HIV positive

- For HCV-negative, healthy volunteers: History of HCV infection or positive HCV antibody test

- Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study

- In the opinion of the investigator, the volunteer is unlikely to comply with the study protocol

- Any clinically significant abnormality or medical history or physical examination including history of immunodeficiency or autoimmune disease (in addition to HCV infection, for HCV group)

- Currently taking systemic steroids or other immunomodulatory medications including anticancer medications and antiviral medications

- Any clinically significant acute or chronic medical condition requiring care by a primary care provider (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation

- Unable to continue participation for 156 weeks

- History of previous Hepatitis B vaccination(s)

- Male or female < 18 and > 62 years of age

- Is pregnant or lactating

- History of Hepatitis B infection

- Clinical, laboratory, or biopsy evidence of cirrhosis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Recombivax
Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment

Locations

Country Name City State
United States Rockefeller University Hospital New York New York

Sponsors (2)

Lead Sponsor Collaborator
Rockefeller University National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary HBV Vaccine Response Versus Non-response Status Titers of anti-hepatitis B surface antigen antibody measured at 8 months
Luminex assay for multiplex cytokine/chemokine panel measured at 8 months RNA-Seq with analysis focus on curated ISG list measured at 8 months
8 months
Secondary Frequency and Functional Status of Anti-HBsAg Antibody-producing B Cells Post-vaccination Doses Over Time ELISPOT assays will measured at 8 months 8 months
Secondary Frequency and Functional Status of HBsAg-specific CD4+ "Helper" T Cells Flow cytometry assays measured at 8 months 8 months
Secondary Functional Response of Monocytes Stimulated ex Vivo With Vaccine Antigen and/or Adjuvant Isolated from patient PBMCs measured at 8 months 8 months
Secondary Gene Expression Profile of Conventional Dendritic Cells Measured by RNA-Seq Isolated from patient PBMCs measured at 8 months 8 months
See also
  Status Clinical Trial Phase
Completed NCT01771653 - Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection N/A
Recruiting NCT03601546 - Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam
Completed NCT02362217 - A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination Phase 1
Completed NCT00513461 - Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection Phase 2
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT02247401 - Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt Phase 3
Completed NCT02582632 - A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults Phase 3
Terminated NCT01532908 - Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C Phase 2
Recruiting NCT01754961 - Effects of Vitamin D on Inflammation in Liver Disease Phase 2
Terminated NCT01465516 - Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir N/A
Completed NCT01265511 - Study of SCY-635, Pegasys and Copegus in Hepatitis C Phase 2
Completed NCT04042740 - Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection Phase 2
Not yet recruiting NCT05601518 - Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.
Not yet recruiting NCT05506475 - Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
Withdrawn NCT02112630 - Boceprevir in End Stage Renal Disease (ESRD) N/A
Terminated NCT01841502 - Interaction Between Paroxetine and Telaprevir Phase 2
Completed NCT02076100 - Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003) Phase 1
Completed NCT01803308 - A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection Phase 1
Terminated NCT01560468 - Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection Phase 1
Active, not recruiting NCT02772003 - DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection Phase 1